Trial Profile
A randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Mitoxantrone (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Cyclophosphamide; Fludarabine; Fludarabine; Lenograstim
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms ARCTIC
- 17 Jun 2021 Results assessing rognostic factors, minimal residual disease (MRD), toxicity and number of treatment cycles affect progression free survival (PFS) and overall survival (OS) in the combined ADMIRE/ARCTIC studies, presented at the 26th Congress of the European Haematology Association.
- 17 Jun 2018 Results (from ADMIRE, ARCTIC, IcICLLe and CLARITY trials) quantifying CLL cell percent of leucytes (%MRD) using 8CLR ERIC-standard flow cytometry (detection limit 10-5/0.001%) presented at the 23rd Congress of the European Haematology Association
- 20 Oct 2012 Accrual to date is 97% according to United Kingdom Clinical Research Network record.